1-8 of 8
Brenda J Chyla, PhD
Close
Sort by
Journal Articles

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Brenda J Chyla, PhD, Jason Harb, PhD, Christine Mantis, PhD, Jacob J Riehm, PhD, Jeremy A. Ross, PhD, Yan Sun, PhD, Xin Huang, PhD MD, Qi Jiang, PhD, Monique Dail, PhD, Franklin V. Peale, Jr., MD PhD, Jalaja Potluri, MD, John Hayslip
Journal: Blood
Blood (2019) 134 (Supplement_1): 546.
https://doi.org/10.1182/blood-2019-128373
Published: 2019
Journal Articles

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Brenda J Chyla, PhD, Relja Popovic, PhD, Charles Lu, PhD, Fengjiao Dunbar, PhD, Danjuma Quarless, PhD, Kenneth Robinson, MS, Scott Warder, PhD, Amanda Jacobson, PhD, Lang Zhou, PhD, Andrew Souers, PhD, Jeffrey Waring, PhD, Anahita Bhathena, PhD, Joel D. Leverson, PhD, Su Young Kim, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 172.
https://doi.org/10.1182/blood-2019-127458
Published: 2019
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019
Journal Articles

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Marina Konopleva, MD PhD, Daniel A. Pollyea, MD MS, Jalaja Potluri, MD, Brenda J. Chyla, PhD, Todd Busman, MS, Evelyn McKeegan, PhD, Ahmed Salem, PhD, Ming Zhu, PhD, Justin L. Ricker, MD PhD, William Blum, MD, Courtney D. DiNardo, MD, Martin Dunbar, DRPH, Rachel Kirby, Nancy Falotico, Joel D. Leverson, PhD, Rod A. Humerickhouse, MD PhD, Mack Mabry, MD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Anthony G. Letai, MD PhD
Journal: Blood
Blood (2014) 124 (21): 118.
https://doi.org/10.1182/blood.V124.21.118.118
Published: 2014
Journal Articles

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study

John F. Seymour, MBBS FRACP, Matthew S. Davids, MD, Mary Ann Anderson, PhD, Thomas J. Kipps, MD, PhD, William G. Wierda, MD, PhD, John M. Pagel, MD, PhD, Brad S. Kahl, M.D., Thomas P. Miller, MD, David E. Darden, MS, Cathy E. Nolan, BS, Lori A. Gressick, BS, Hao Xiong, PhD, David C.S. Huang, MB BS MRCP PhD, Brenda J. Chyla, PhD, Todd A. Busman, MS, Alison M. Graham, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2012) 120 (21): 3923.
https://doi.org/10.1182/blood.V120.21.3923.3923
Published: 2012
Journal Articles

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

Matthew S. Davids, MD, Andrew W. Roberts, MD, PhD, Mary Ann Anderson, PhD, John M. Pagel, MD, PhD, Brad S. Kahl, M.D., John F. Gerecitano, MD, PhD, David E. Darden, MS, Cathy E. Nolan, BS, Lori A. Gressick, BS, Jianning Yang, PhD, Brenda J. Chyla, PhD, Todd A. Busman, MS, Alison M. Graham, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, John F. Seymour, MBBS FRACP
Journal: Blood
Blood (2012) 120 (21): 304.
https://doi.org/10.1182/blood.V120.21.304.304
Published: 2012
Journal Articles

Loss of Bcl-x Does Not Ameliorate Chronic Myeloid Leukemia in an Inducible Murine Model System.

Brenda J. Chyla, PhD, Jason G. Harb, Ph.D., Claudia S. Huettner, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 1000.
https://doi.org/10.1182/blood.V110.11.1000.1000
Published: 2007
Journal Articles

Genetic Deletion of Bcl-x Reveals a Potential Role in Governing Stem Cell Homeostasis.

Brenda J. Chyla, PhD, Jason G. Harb, Ph.D., Claudia S. Huettner, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 1349.
https://doi.org/10.1182/blood.V108.11.1349.1349
Published: 2006